Life Science Investing Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
Life Science Investing Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
Life Science Investing Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
Surface Metals Inc. Sells Remaining Interest in Manitoba Lithium Project to Earn-in Partner Snow Lake Energy
Nine Mile Metals Announces Completion of DDH WD-25-02B and Continues to Confirm Zones of Copper Rich VMS with 66 Meters of Mineralization at the Wedge Project
